110 related articles for article (PubMed ID: 10608800)
1. Safety and immune responses to a DNA-based human immunodeficiency virus (HIV) type I env/rev vaccine in HIV-infected recipients: follow-up data.
MacGregor RR; Boyer JD; Ciccarelli RB; Ginsberg RS; Weiner DB
J Infect Dis; 2000 Jan; 181(1):406. PubMed ID: 10608800
[No Abstract] [Full Text] [Related]
2. Robust HIV-specific immune responses were induced by DNA vaccine prime followed by attenuated recombinant vaccinia virus (LC16m8 strain) boost.
Shinoda K; Xin KQ; Kojima Y; Saha S; Okuda K; Okuda K
Clin Immunol; 2006 Apr; 119(1):32-7. PubMed ID: 16458074
[TBL] [Abstract][Full Text] [Related]
3. Gene combination raises broad human immunodeficiency virus-specific cytotoxicity.
Calarota SA; Kjerrström A; Islam KB; Wahren B
Hum Gene Ther; 2001 Sep; 12(13):1623-37. PubMed ID: 11535166
[TBL] [Abstract][Full Text] [Related]
4. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.
Letvin NL; Huang Y; Chakrabarti BK; Xu L; Seaman MS; Beaudry K; Korioth-Schmitz B; Yu F; Rohne D; Martin KL; Miura A; Kong WP; Yang ZY; Gelman RS; Golubeva OG; Montefiori DC; Mascola JR; Nabel GJ
J Virol; 2004 Jul; 78(14):7490-7. PubMed ID: 15220422
[TBL] [Abstract][Full Text] [Related]
5. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
6. Comparative immunogenicity of human immunodeficiency virus particles and corresponding polypeptides in a DNA vaccine.
Akahata W; Yang ZY; Nabel GJ
J Virol; 2005 Jan; 79(1):626-31. PubMed ID: 15596858
[TBL] [Abstract][Full Text] [Related]
7. Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines.
Boyer JD; Cohen AD; Vogt S; Schumann K; Nath B; Ahn L; Lacy K; Bagarazzi ML; Higgins TJ; Baine Y; Ciccarelli RB; Ginsberg RS; MacGregor RR; Weiner DB
J Infect Dis; 2000 Feb; 181(2):476-83. PubMed ID: 10669329
[TBL] [Abstract][Full Text] [Related]
8. Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model.
Earl PL; Wyatt LS; Montefiori DC; Bilska M; Woodward R; Markham PD; Malley JD; Vogel TU; Allen TM; Watkins DI; Miller N; Moss B
Virology; 2002 Mar; 294(2):270-81. PubMed ID: 12009868
[TBL] [Abstract][Full Text] [Related]
9. Development of a candidate DNA/MVA HIV-1 subtype C vaccine for India.
Kumar S; Aggarwal P; Vajpayee M; Pandey RM; Seth P
Vaccine; 2006 Mar; 24(14):2585-93. PubMed ID: 16480792
[TBL] [Abstract][Full Text] [Related]
10. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
[TBL] [Abstract][Full Text] [Related]
11. DNA vaccination of macaques by a full genome HIV-1 plasmid which produces noninfectious virus particles.
Akahata W; Ido E; Shimada T; Katsuyama K; Yamamoto H; Uesaka H; Ui M; Kuwata T; Takahashi H; Hayami M
Virology; 2000 Sep; 275(1):116-24. PubMed ID: 11017793
[TBL] [Abstract][Full Text] [Related]
12. A peptide-loaded dendritic cell based cytotoxic T-lymphocyte (CTL) vaccination strategy using peptides that span SIV Tat, Rev, and Env overlapping reading frames.
Klase Z; Donio MJ; Blauvelt A; Marx PA; Jeang KT; Smith SM
Retrovirology; 2006 Jan; 3():1. PubMed ID: 16398928
[TBL] [Abstract][Full Text] [Related]
13. An open label, phase I/II clinical trial to evaluate the safety and biological activity of HIV-IT (V) (HIV-1IIIBenv/rev retroviral vector) in HIV-1-infected subjects.
Haubrich R; McCutchan JA; Holdredge R; Heiner L; Merritt J; Merchant B
Hum Gene Ther; 1995 Jul; 6(7):941-55. PubMed ID: 7578412
[No Abstract] [Full Text] [Related]
14. Long-term persistence of vaccination and HAART to human immunodeficiency virus (HIV).
Boström AC; Hejdeman B; Matsuda R; Fredriksson M; Fredriksson EL; Bratt G; Sandström E; Wahren B
Vaccine; 2004 Apr; 22(13-14):1683-91. PubMed ID: 15068851
[TBL] [Abstract][Full Text] [Related]
15. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.
AIDS Vaccine Evaluation Group 022 Protocol Team
J Infect Dis; 2001 Feb; 183(4):563-70. PubMed ID: 11170981
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine.
Cristillo AD; Wang S; Caskey MS; Unangst T; Hocker L; He L; Hudacik L; Whitney S; Keen T; Chou TH; Shen S; Joshi S; Kalyanaraman VS; Nair B; Markham P; Lu S; Pal R
Virology; 2006 Mar; 346(1):151-68. PubMed ID: 16325880
[TBL] [Abstract][Full Text] [Related]
17. AIDS vaccine boosts immunity in HIV patients.
RN; 1991 Oct; 54(10):103. PubMed ID: 1925340
[No Abstract] [Full Text] [Related]
18. HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies.
Bower JF; Li Y; Wyatt R; Ross TM
Vaccine; 2006 Jun; 24(26):5442-51. PubMed ID: 16621193
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of cellular immune response in HIV-1 seropositive individuals: A DNA-based trial.
Boyer JD; Chattergoon MA; Ugen KE; Shah A; Bennett M; Cohen A; Nyland S; Lacy KE; Bagarazzi ML; Higgins TJ; Baine Y; Ciccarelli RB; Ginsberg RS; MacGregor RR; Weiner DB
Clin Immunol; 1999 Jan; 90(1):100-7. PubMed ID: 9884357
[TBL] [Abstract][Full Text] [Related]
20. Retroviral vectors for HIV immunotherapy.
Warner JF; Jolly D; Mento S; Galpin J; Haubrich R; Merritt J
Ann N Y Acad Sci; 1995 Nov; 772():105-16. PubMed ID: 8546383
[No Abstract] [Full Text] [Related]
[Next] [New Search]
